https://doi.org/10.4081/amsa.2023.36
Levosimendan off-label successfully used in two patients with exacerbated COPD and severe bronchospasm: a case series focusing on an explorative review of the current literature
Submitted: 28 September 2023
Accepted: 7 November 2023
Published: 17 November 2023
Accepted: 7 November 2023
Abstract Views: 361
PDF: 69
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Levosimendan was used off label to treat two patients with similar clinical and medical history (severe COPD, bronchospasm, cigarette smoking, difficult weaning). Starting from these two favorable cases, an explorative review of the current literature was conducted relating to this use of Levosimendan and its rationale.
Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013;5:227-45.
Pienkowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
DOI: https://doi.org/10.1093/eurheartj/ehw128
American Thoracic Society. Heart drug offers possible treatment for patients facing respiratory failure. ScienceDaily 2011. Available from: https://www.sciencedaily.com/releases/2011/09/110923095806.htm
Babik B, Balogh AL, Sudy R, et al. Levosimendan prevents bronchoconstriction and adverse respiratory tissue mechanical changes in rabbits. Am J Physiol Lung Cell Mol Physiol 2017;313:L950-L956.
DOI: https://doi.org/10.1152/ajplung.00213.2017
Van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:41-7.
DOI: https://doi.org/10.1164/rccm.200805-732OC
Zambelli V, Murphy EJ, Delvecchio P, et al. Treatment with levosimendan in an experimental model of early ventilator-induced diaphragmatic dysfunction. Drug Target Insights 2023;17:39-44.
DOI: https://doi.org/10.33393/dti.2023.2574
Ouanes-Besbes L, Ouanes I, Dachraoui F, et al. Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine. J Crit Care 2011;26:15-21.
DOI: https://doi.org/10.1016/j.jcrc.2010.01.002
Doorduin J, Sinderby CA, Beck J, et al. The calcium sensitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med 2012;185:90-5.
DOI: https://doi.org/10.1164/rccm.201107-1268OC
Bruells CS, Marx G, Rossaint R. Ventilatorinduzierte diaphragmale Dysfunktion: Klinisch relevantes Problem [Ventilator-induced diaphragm dysfunction : clinically relevant problem]. Anaesthesist 2014;63:47-53.
DOI: https://doi.org/10.1007/s00101-013-2248-9
How to Cite
Golino, L., Caiazzo, M., Diglio, P., Tornincasa, E., Russo, G., & Imperatore, F. (2023). Levosimendan off-label successfully used in two patients with exacerbated COPD and severe bronchospasm: a case series focusing on an explorative review of the current literature. Acute Care Medicine Surgery and Anesthesia, 1(1). https://doi.org/10.4081/amsa.2023.36
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.